Development of Biosimilars

Forming a new company with Lupin
to work together on the clinical development of biosimilars

Yoshindo founded YL Biologics together with Lupin in 2014 with the aim of developing and manufacturing biosimilars. The first drug we have chosen to develop a biosimilar for is Enbrel which is used to treat rheumatoid arthritis. This was implemented via Lupin Limited and is currently being clinically developed in Japan and aiming for approval to be sold within the country.